Format

Send to

Choose Destination
Euro Surveill. 2010 May 6;15(18). pii: 19561.

Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010.

Author information

1
Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany. WichmannO@rki.de

Abstract

During the 2009 influenza pandemic, a monovalent AS03-adjuvanted vaccine was almost exclusively used in Germany for immunisation against the 2009 pandemic influenza A(H1N1) virus. One-dose vaccination was recommended for all age groups. We applied the screening method for the rapid assessment of vaccine effectiveness (VE) based on reported data of vaccinated and unvaccinated pandemic influenza cases and vaccination coverage estimates. Preliminary results demonstrate excellent VE in persons aged 14-59 years (96.8%; 95% confidence interval (CI): 95.2-97.9) and moderately high VE in those 60 years or older (83.3%; 95% CI: 71.0-90.5).

PMID:
20460094
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for European Centre for Disease Prevention and Control (ECDC)
Loading ...
Support Center